Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility
ECONOMY & POLICY

Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility

Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.

The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.

In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.

Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.

Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.

News source: The Hindu


Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.News source: The Hindu

Next Story
Infrastructure Energy

Vedanta Aluminium Uses 1.57 bn Units of Green Energy in FY25

Vedanta Aluminium, India’s largest aluminium producer, recently reported consumption of 1.57 billion units of renewable energy in FY25, marking a significant milestone in its 2030 decarbonisation roadmap. The company also achieved an 8.96 per cent reduction in greenhouse gas (GHG) emissions intensity compared to FY21, reinforcing its leadership in India’s low-carbon manufacturing transition. During FY25, Vedanta Aluminium expanded its renewable energy portfolio through long-term power purchase agreements, strengthening its strategy to source nearly 1,500 MW of renewable power over the lon..

Next Story
Real Estate

Oberoi Group to Develop Luxury Resort at Makaibari Tea Estate

EIH Limited, the flagship company of The Oberoi Group, has announced the signing of a management agreement to develop an Oberoi luxury resort at the iconic Makaibari Tea Estate in Darjeeling. The project marks a key milestone in the Group’s long-term strategy of creating distinctive hospitality experiences in rare and environmentally significant locations. Established in 1859, Makaibari is one of the world’s oldest tea estates and is globally recognised for its Himalayan landscape, primary forests and exceptional biodiversity. Spread across 1,236 acres, the estate houses one of the world..

Next Story
Real Estate

GHV Infra Secures Rs 1.09 Bn EPC Order in Jamshedpur

GHV Infra Projects Ltd, a fast-growing EPC company in India’s infrastructure and construction sector, has recently secured a Rs 1.09 billion work order in Jamshedpur, Jharkhand. Awarded by a reputed group entity, the contract covers end-to-end civil construction, mechanical, electrical and plumbing (MEP) systems, along with high-quality finishing works for a large building development. The project will be executed over a 30-month period, with defined benchmarks for quality, safety and timely delivery. The order strengthens GHV Infra’s footprint in Jamshedpur, a key industrial hub known fo..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Open In App